Aurinia Pharmaceuticals Inc (AUPH)

[biotech_researcher]

Cantor is screwy with some of their data:

Investment Summary: We are reiterating our Overweight rating and increasing our price target on AUPH to $16/share from $14/share, following the 4Q17 financial release and reduction of the estimated tax rate to 21% from 35%.

They raised their target based SOLELY on the tax rate dropping from 35% to 21%. AURINIA pays zero taxes as they have zero revenue.

Further down, they claim 278 million individuals have SLE. Really?

I expect a human did not generate that report...